Skip to content Skip to sidebar Skip to footer
telix
Telix Pharmaceuticals (ASX:TLX) Through the Commercialisation Chasm
The Market Lost Patience, the Strategy Did Not Telix Pharmaceuticals (ASX:TLX) is one of the more compelling examples of a biotech company pushing through the commercialisation chasm, often the most difficult phase in the sector’s lifecycle. This is the point where companies transition from deep, equity-funded cash burn into sustainable revenue generation, and many fail…
Imricor
Imricor Medical (ASX:IMR) FDA Approval Ignites Shares, but the Real Test Starts Now
FDA Approval Is a Big Win, Not the Finish Line Imricor Medical (ASX:IMR) received FDA clearance for its Vision-MR diagnostic catheter, marking the company’s first regulatory approval in the US and a significant milestone in its commercial journey. This approval enables Imricor to begin commercial rollout of the catheter, and the market responded positively, with…

Stocks Down Under (Pitt Street Research AFSL 1265112) provides actionable investment ideas on ASX-listed stocks. This content provides general information only and does not constitute financial advice. Always do your own research before making investment decisions. © 2026 Stock Down Under. All Rights Reserved.

© 2026 Kicker. All Rights Reserved.

Add Your Heading Text Here